user-group INVESTOR ACCESS
Search
Close this search box.
  1. Home
  2. /
  3. Venture Capital
  4. /
  5. MRM Health Reports Positive...

News / Venture Capital

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis

19 September 2023
MRM Health NV, a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics, today reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis (UC).

Download

Press Release
Download

Related News

  • Venture Capital
  • Other news

Private Corner lance un feeder sur le thème de la santé avec Mérieux Equity Partners, pour son fonds Mérieux Innovation 2

arrow-up-right
  • Venture Capital
  • Other news

The Mérieux Innovation 2 fund is awarded the Tibi label, in recognition of its support to healthcare innovation in France and Europe, for the benefit of patients.

arrow-up-right
  • Buyout
  • Other news

Integrating Nature: at the heart of our “One Health” approach.

arrow-up-right
Lyon
Paris
Contact
  • ⓒ MERIEUX EQUITY PARTNERS 2023
  • Mérieux Equity Partners vehicles are only open to Professional Clients - as defined in the French Monetary code (CMF) and AMF regulation (RG).